M-L Dahl

Karolinska University Hospital — Sweden

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

10h-index1.1kcitations16works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacogenetics and Drug Metabolism(9), Schizophrenia research and treatment(4), Epilepsy research and treatment(3), Pharmacological Effects and Toxicity Studies(3), Diet and metabolism studies(3)

Publications16 total

TDM of psychoactive drugs in Sweden
Pharmacopsychiatry·2016
Abstract PD10-09: CYP2D6 and adjuvant tamoxifen: Impact on outcome in pre- but not postmenopausal breast cancer patients
Cancer Research·2012· 1 cited
Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients
The Pharmacogenomics Journal·2012· 28 cited
Pharmacodynamics of Carbamazepine-mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam, Caffeine, and Digoxin
Clinical Pharmacology & Therapeutics·2007· 94 cited
A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy
Clinical Pharmacology & Therapeutics·2007· 142 cited
Therapeutic monitoring of antiepileptic drugs for epilepsy
Cochrane Database of Systematic Reviews·2006· 18 cited
Disposition of debrisoquine and nortriptyline in Korean subjects in relation to <i>CYP2D6</i> genotypes, and comparison with Caucasians
British Journal of Clinical Pharmacology·2003· 15 citedOpen Access
Intra-individual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes
The Pharmacogenomics Journal·2002· 42 cited
Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.
British Journal of Clinical Pharmacology·1995· 59 citedOpen Access
Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19.
British Journal of Clinical Pharmacology·1995· 184 citedOpen Access
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
British Journal of Clinical Pharmacology·1994· 306 citedOpen Access
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
The Lancet·1993· 225 cited
[Genotyping for drug metabolism capacity can give valuable clinical information].
PubMed·1992· 2 cited
[Knowledge about metabolic capacity is important in drug therapy].
PubMed·1992
[Abuse potential of benzodiazepines. Sensible use means continuous follow-up].
PubMed·1990
U-60,257 has no effect on the metabolism of arachidonic acid in nonstimulated human polymorphonuclear leukocytes.
PubMed·1984· 1 cited

Frequent Co-authors

Leif Bertilsson(5), Folke Sjöqvist(3), Adrián LLerena(2), Inger Johansson(2), Magnus Ingelman‐Sundberg(2), Gunnel Tybring(2), JA Carrillo(1), C. Alm(1), Ulf Bondesson(1), L. Lindström(1), I Rodriguez de la Rubia(1), Sara Ramos(1), J. Benítez(1), Anna Åberg‐Wistedt(1), Mats B. Humble(1), Eva Lundqvist(1), Ming Chang(1), E. Götharson(1), M. Sagar(1), Rein Seensalu(1)